https://www.businesswire.com/news/home/20180524005272/en/

NEWARK, Calif.--(BUSINESS WIRE)--May 24, 2018--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that results of a Phase 2 study of DaxibotulinumtoxinA for Injection (RT002) to treat moderate-to-severe cervical dystonia (CD) have been published in the peer-reviewed journal Movement Disorders Clinical Practice ( https://onlinelibrary.wiley.com/doi/epdf/10.1002/mdc3.12613 ).

These positive 24-week results from a Phase 2 open-label, dose-escalating study were announced in May 2017 and were formally presented at the 21 st International Congress of Parkinson’s Disease and Movement Disorders in June 2017. The previously reported findings demonstrate that RT002 injectable provided clinically significant improvement in the signs and symptoms of CD as determined by reduction of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score from baseline. In addition, RT002 was found to be generally safe and well-tolerated.